Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 9/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19975136 | 0.95 | EPHX1 (0.40) | PTGIREPHX1 | |
| SCHEMBL19975208 | 0.95 | EPHX1 (0.43) | EPHX1 | |
| SCHEMBL19975148 | 0.94 | EPHX1 (0.45) | EPHX1 | |
| SCHEMBL19975529 | 0.88 | PTGIR (0.40) | PTGIRCYP2C19EPHX1KDM1ARCOR1 | |
| SCHEMBL19975512 | 0.88 | PTGIR (0.40) | PTGIRSIGMAR1 | |
| SCHEMBL28316641 | 0.88 | SMN1; SMN2 (0.45) | PTGIREPHX1 | |
| SCHEMBL19975287 | 0.87 | PTGIR (0.47) | PTGIR | |
| SCHEMBL19975567 | 0.86 | ALDH1A1 (0.46) | PTGIREPHX1 | |
| SCHEMBL28315310 | 0.86 | SMN1; SMN2 (0.36) | PTGIREPHX1 | |
| SCHEMBL19974724 | 0.85 | PTGIR (0.40) | PTGIRCYP2C19EPHX1KDM1ARCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2022-11-10 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | PTGIR 540/4885CYP2C19 3198/4885EPHX1 372/4885 |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | PLA2G12A, PLA2G1B, PLA2G4C | PTGIR 679/4885CYP2C19 3143/4885EPHX1 449/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | PTGIR 540/4885CYP2C19 3198/4885EPHX1 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.